Europe's drug regulator decided to allow the Sanofi-Aventis weight-loss drug Acomplia to stay on the market there but said it is to be denied to people with depression. The U.S. FDA earlier rejected approval of the drug because of its side effect of suicidal thoughts, and Sanofi decided to abandon its pursuit of U.S. approval. The European Medicines Agency said it would require harsher warnings about the drug's dangers.

Related Summaries